KaloCyte, Inc.
About
KaloCyte is on a mission to develop a shelf-stable bioengineered artificial red blood cell as a lifeline when blood is not available.
KaloCyte is a pre-clinical biotech therapeutic startup company developing ErythroMer, a bioengineered artificial red blood cell (RBC) substitute that can be freeze-dried for long-term storage and is envisioned for pre-hospital treatment of traumatic hemorrhage when stored blood is unavailable or undesirable. Funded by $14M in grants from DARPA and NIH, and over $5M investor funding, we are currently focused on de-risking and scale up, armed with confirmation of our IND approach following a successful pre-IND meeting with FDA.
Gallery

Powered By GrowthZone